Walleye Capital LLC Buys Shares of 105,335 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Walleye Capital LLC purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 105,335 shares of the company’s stock, valued at approximately $4,740,000.

A number of other large investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in shares of Protagonist Therapeutics during the first quarter worth $35,000. Vanguard Group Inc. lifted its position in Protagonist Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock valued at $92,373,000 after purchasing an additional 39,055 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in Protagonist Therapeutics by 74.2% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 9,083 shares of the company’s stock worth $263,000 after purchasing an additional 3,870 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Protagonist Therapeutics in the first quarter valued at $69,000. Finally, SG Americas Securities LLC acquired a new position in Protagonist Therapeutics in the 2nd quarter worth about $379,000. 98.63% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Wedbush restated an “outperform” rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. TD Cowen raised Protagonist Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 25th. Truist Financial began coverage on shares of Protagonist Therapeutics in a research report on Monday, September 9th. They set a “buy” rating and a $60.00 price target on the stock. StockNews.com raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, JMP Securities decreased their target price on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 7th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $53.57.

Insider Buying and Selling at Protagonist Therapeutics

In other news, insider Arturo Md Molina sold 1,906 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $40.98, for a total value of $78,107.88. Following the completion of the sale, the insider now directly owns 46,444 shares of the company’s stock, valued at approximately $1,903,275.12. The trade was a 3.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $540,000. This trade represents a 40.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 232,066 shares of company stock worth $10,681,738 over the last three months. Insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Stock Performance

PTGX opened at $43.80 on Monday. Protagonist Therapeutics, Inc. has a one year low of $17.70 and a one year high of $48.89. The company has a market cap of $2.61 billion, a P/E ratio of 16.47 and a beta of 2.17. The business’s 50-day simple moving average is $45.15 and its 200-day simple moving average is $39.89.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.